Bone Res:仿生双相CAN-PAC水凝胶可用于软骨缺损修复

2017-08-16 MedSci MedSci原创

基于仿生支架的软骨组织工程已成为修复软骨缺陷的一个重要方法。在本研究中,研究人员通过热反应快速交联方法,利用两层之间的密度差制备了用于软骨缺损(OCD)再生的双相CAN-PAC水凝胶。上水凝胶通过CSMA和NIPAm交联,下水凝胶由PECDA,AAm和PEGDA组成。两层之间的界面首先通过葡萄糖酸钙和藻酸盐的物理交联连接,然后在其它组分中进行碳-碳双键的化学交联。上下水凝胶的孔径分别为〜187.4

基于仿生支架的软骨组织工程已成为修复软骨缺陷的一个重要方法。

在本研究中,研究人员通过热反应快速交联方法,利用两层之间的密度差制备了用于软骨缺损(OCD)再生的双相CAN-PAC水凝胶。上水凝胶通过CSMA和NIPAm交联,下水凝胶由PECDA,AAm和PEGDA组成。两层之间的界面首先通过葡萄糖酸钙和藻酸盐的物理交联连接,然后在其它组分中进行碳-碳双键的化学交联。上下水凝胶的孔径分别为〜187.4和〜112.6μm,模量为〜0.065和〜0.261MPa。

这种双层水凝胶的模拟组成、模拟结构和模拟刚度的特征,提供了维持细胞附着和活力的微环境。同时,研究人员还在体内检查了CAN-PAC水凝胶的生物降解性和生物相容性。并建立了兔软骨缺损模型,将双层水凝胶植入了缺损。

总之,该研究显示,双层水凝胶组的再生组织出现了新的半透明软骨和软骨下骨修复,表明水凝胶可以增强软骨缺损的修复。

原始出处:

Jinfeng Liao,1 Taoran Tian, et al., The fabrication of biomimetic biphasic CAN-PAC hydrogel with a seamless interfacial layer applied in osteochondral defect repair. Bone Res. 2017; 5: 17018. Published online 2017 Jul 4. doi:  10.1038/boneres.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1915159, encodeId=73cf191515931, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Mar 23 16:03:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307999, encodeId=054f130e99914, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Aug 18 01:03:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419234, encodeId=a9e9141923405, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Fri Aug 18 01:03:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460935, encodeId=0137146093569, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Aug 18 01:03:00 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
    2018-03-23 apoenzyme
  2. [GetPortalCommentsPageByObjectIdResponse(id=1915159, encodeId=73cf191515931, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Mar 23 16:03:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307999, encodeId=054f130e99914, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Aug 18 01:03:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419234, encodeId=a9e9141923405, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Fri Aug 18 01:03:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460935, encodeId=0137146093569, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Aug 18 01:03:00 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
    2017-08-18 tastas
  3. [GetPortalCommentsPageByObjectIdResponse(id=1915159, encodeId=73cf191515931, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Mar 23 16:03:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307999, encodeId=054f130e99914, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Aug 18 01:03:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419234, encodeId=a9e9141923405, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Fri Aug 18 01:03:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460935, encodeId=0137146093569, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Aug 18 01:03:00 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
    2017-08-18 lfcmxl
  4. [GetPortalCommentsPageByObjectIdResponse(id=1915159, encodeId=73cf191515931, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Mar 23 16:03:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307999, encodeId=054f130e99914, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Aug 18 01:03:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419234, encodeId=a9e9141923405, content=<a href='/topic/show?id=2e2e10182602' target=_blank style='color:#2F92EE;'>#骨缺损#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101826, encryptionId=2e2e10182602, topicName=骨缺损)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51173492599, createdName=lfcmxl, createdTime=Fri Aug 18 01:03:00 CST 2017, time=2017-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460935, encodeId=0137146093569, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Fri Aug 18 01:03:00 CST 2017, time=2017-08-18, status=1, ipAttribution=)]
    2017-08-18 hb2008ye

相关资讯

Biomaterials:热降解水凝胶实现药物按需递送

水凝胶材料近年来在生物医药领域受到了广泛关注,例如作为药物递送载体、组织再生支架、外科手术缝合胶等。负载药物的水凝胶可在体内保持数日乃至数周的持续释放,很大程度上提高了药物的利用度和病人的耐受性,并降低药物毒副作用。如在水凝胶材料中引入酸、酶、光、热等刺激响应元件,则可进一步赋予水凝胶药物载体更加灵活可变的药物控制释放性能。近日,华东师范大学的程义云教授团队研发出一种可在43摄氏度的条件下快速降解

ADV HEALTHC MATER:可快速血管化的水凝胶静电纺纤维支架

糖尿病患者经常面临皮肤创面,尤其是足部创面难以愈合并最终形成糖尿病溃疡的风险,这是最常见也是最严重的糖尿病并发症之一。根据2015年WHO最新统计报告显示,中国糖尿病患者数量已突破1亿人,皮肤软组织缺损的病例亦是逐年递增,而如何让创面能够快速愈合并恢复正常成为临床上的棘手问题。其中,缺损区域周边的血管病变及新生血管减少是导致缺损难愈合的最重要的局部原因之一。随着对于糖尿病患者血管病变机理研究的深入

Nature:利用一种新的水凝胶在体外培养类器官

在一项新的研究中,来自瑞士洛桑联邦理工学院(EPFL)的研究人员开发出一种培养微型化身体器官的水凝胶,所培养出的微型化身体器官能够用于临床诊断和药物开发之中。 类器官(organoid)是能够在实验室中利用人的干细胞培养出的微型器官。它们能够被用来构建疾病模型,而且在未来可能被用来测试药物或者甚至替换病人体内受损的组织。但是当前的类器官在一种标准化的可控方法中非常难以培养,其中这种方法是设计和使

Basic Clin Androl:一种男性注射避孕药能有效阻止怀孕

为了进行更好的生育控制和吸引美国硅谷数百万美元的投资,科学家一直在开发一种男性避孕药。如今,在一项新的研究中,来自美国加州大学戴维斯分校的研究人员证实Vasalgel水凝胶能够注射到雄性恒河猴输精管中阻断精子,似乎会阻止雌性恒河猴怀孕,而且比输精管切除术具有更少的副作用。相关研究结果于2017年2月7日发表在Basic and Clinical

Small:智能水凝胶薄膜,一种恶性肿瘤血液检测的新方法

生物界面的设计在疾病诊断、生物医药、组织工程等领域都有十分重要的意义。传统的生物界面设计或着眼于表面化学的调控,或关注于表面拓扑结构的构筑。若将两者相结合则可以显着提高生物界面的性能,比如在纳米结构基底上修饰响应性分子能极大提高循环肿瘤细胞的捕获和释放效率。然而,这样的生物界面往往需要先构筑表面微纳米结构,再进行表面化学修饰;对外界响应主要由化学修饰实现。如何实现表面化学和结构的同时调控成为一个难

ADV FUNCT MATER:高强高韧矿化水凝胶,颅骨修复的新思路

颅骨缺损是最常见和多样性的人类先天性异常之一,严重影响患者的生活质量,特别是创伤、肿瘤切除和血管损伤等造成的大面积的颅骨缺损。目前,颅骨损伤采用的最常见的治疗手段为自体骨和同种异体骨移植。然而,自体骨移植往往面临着形状匹配和来源有限的难题,同种异体骨移植容易引起免疫排斥反应。基于此,很多材料例如生物活性陶瓷、钛网、合成高分子或者它们的复合材料被尝试用于颅骨缺损修复,虽然一定程度上解决了自体和异体骨